148 related articles for article (PubMed ID: 15201384)
1. Local pain during REBIF injection is not due to acidic pH.
Buttmann M; Goebeler M; Rieckmann P
J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1078. PubMed ID: 15201384
[No Abstract] [Full Text] [Related]
2. [PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
Hartung HP; Flachenecker P; Weilbach FX; Rieckmann P
Nervenarzt; 1999 Feb; 70(2):182-5. PubMed ID: 10098156
[No Abstract] [Full Text] [Related]
3. Local reactions after subcutaneous injections of beta-interferon.
van Rengen A; Goossens A
Contact Dermatitis; 1998 Oct; 39(4):209. PubMed ID: 9817241
[No Abstract] [Full Text] [Related]
4. Depression in multiple sclerosis associated with interferon beta-1a (Rebif).
Pandya R; Patten S
Can J Psychiatry; 2002 Sep; 47(7):686. PubMed ID: 12355685
[No Abstract] [Full Text] [Related]
5. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.
Heinzerling L; Dummer R; Burg G; Schmid-Grendelmeier P
Eur J Dermatol; 2002; 12(2):194-7. PubMed ID: 11872423
[TBL] [Abstract][Full Text] [Related]
6. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
7. Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b.
García-F-Villalta M; Daudén E; Sánchez J; Fraga J; Ramo C; García-Díez A
Acta Derm Venereol; 2001 May; 81(2):152. PubMed ID: 11501663
[No Abstract] [Full Text] [Related]
8. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
Nakamura Y; Kawachi Y; Furuta J; Otsuka F
Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous necrosis associated with recombinant interferon injection.
Weinberg JM
J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):807-8. PubMed ID: 9810903
[No Abstract] [Full Text] [Related]
10. Fixed drug eruption with interferon-beta-1b.
Tai YJ; Tam M
Australas J Dermatol; 2005 Aug; 46(3):154-7. PubMed ID: 16008645
[TBL] [Abstract][Full Text] [Related]
11. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
12. [Interferons beta in patients with multiple sclerosis].
Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
[No Abstract] [Full Text] [Related]
13. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
Logan-Clubb L; Stacy M
J Neurosci Nurs; 1995 Dec; 27(6):344-7. PubMed ID: 8770778
[TBL] [Abstract][Full Text] [Related]
14. Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Devonshire VA; Verdun di Cantogno E
Ther Deliv; 2011 Nov; 2(11):1455-65. PubMed ID: 22844681
[TBL] [Abstract][Full Text] [Related]
15. [Activation of psoriasis in patients undergoing treatment with interferon-beta].
Navne JE; Hedegaard U; Bygum A
Ugeskr Laeger; 2005 Aug; 167(32):2903-4. PubMed ID: 16109199
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
17. Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis.
Feldmann R; Löw-Weiser H; Duschet P; Gschnait F
Dermatology; 1997; 195(1):52-3. PubMed ID: 9267740
[TBL] [Abstract][Full Text] [Related]
18. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
Tremlett HL; Oger J
Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
[TBL] [Abstract][Full Text] [Related]
19. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.
Chofflon M; Ben-Amor AF
Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662
[No Abstract] [Full Text] [Related]
20. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Hu X; Shang S; Nestorov I; Hasan J; Seddighzadeh A; Dawson K; Sperling B; Werneburg B
Br J Clin Pharmacol; 2016 Aug; 82(2):380-8. PubMed ID: 27060836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
